加倍剂量福辛普利强化治疗蛋白尿的研究

Effect of Proteinuria Treated with Intensive Double Doses of Fosinopril Therapy

目的:研究加倍剂量福辛普利对蛋白尿的强化治疗作用及其安全性。方法:原发性肾病患者随机分为2组,分别给予福辛普利10mg、20mg治疗12周,每3周检测尿蛋白、血压、血钾、血肌酐。结果:①12周后加倍剂量组尿蛋白下降幅度达(57.9±5.1)%,显著高于单倍剂量组(41.5±3.5)% (P<0.01);②两组血压均有显著下降,但两组间无显著差异;③两组血清肌酐、血钾无明显差异。结论:加倍剂量福辛普利较单倍剂量福辛普利有更好的降蛋白尿作用,且加倍剂量对血压能进一步下降但无统计学差异,对肾功能和血钾无不良影响。

Objective：To investigate the antiproteinuric effect and safety of double doses of fosinopril by a randomized controlled study.Methods：The patients with primary glomerular diseases were randomly divided into two groups and used fosinopril in two different dosages（10mg/d and 20mg/d） for 12 weeks.Blood pressure,proteinuria,serum creatinine,and serum potassium were measured every 3 weeks.Results：（1）Double doses of fosinopril exerted more significant aniproteinuric effect compared to the single dose group [（57.9±5.1）% vs（41.5±3.5）%,P0.01] after 12 weeks treatment.（2） The blood preasure reduction between the two groups had no remarkable difference（P0.05）.（3）During observation period,serum creatinine and serum potassium in double doses group had no significant increase compared to the single dose group.Conclusion：The double doses of fosinopril had an superior aniproteinuric effect than the single dose and it is secure.